For the quarter ending 2025-09-30, ENZN has $43,693K in assets. $43,256K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 43,256 | 44,294 | ||
| Other current assets | 411 | 444 | ||
| Total current assets | 43,667 | 44,738 | ||
| Deferred tax asset | 26 | 42 | ||
| Total assets | 43,693 | 44,780 | ||
| Accounts payable | 331 | 331 | ||
| Accrued expenses and other current liabilities | 209 | 472 | ||
| Total current liabilities | 540 | 803 | ||
| Series c preferred stock - 0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value 1,102 and 1,062 per share) at september 30, 2025 and december 31, 2024-Series CPreferred Stock | 44,076 | 43,545 | ||
| Common stock - 0.01 par value, authorized 170,000,000 shares issued and outstanding 74,214,603 shares at september 30, 2025 and december 31, 2024 | 742 | 742 | ||
| Additional paid-in capital | 70,565 | 71,096 | ||
| Accumulated deficit | -72,230 | -71,406 | ||
| Total stockholders' (deficit) equity | -923 | 432 | ||
| Total liabilities, mezzanine equity and stockholders' (deficit) equity | 43,693 | 44,780 | ||
ENZON PHARMACEUTICALS, INC. (ENZN)
ENZON PHARMACEUTICALS, INC. (ENZN)